

LOOKING FOR A **CRO** WITH **END-TO-END** **BA/BE EXPERTISE?**

Partner with a Globally Trusted CRO from **India**
with **25 Years of Legacy** for Scale, Speed, and Compliance

7500+ BA/BE Studies completed

End-to-end execution:
Feasibility to Reporting

Inspected by USFDA, EMA, WHO,
MHRA, ANVISA, AGES & others.

Diverse Volunteer Database -
Healthy, Elderly, PM &
Surgically Sterile Females


Expertise in **Complex**
Generics & Biosimilars




CPUs
in India
& USA

BA/BE EXPERTISE ACROSS HEALTHY VOLUNTEERS AND PATIENT POPULATIONS


EXPERIENCE ACROSS DIVERSE DOSAGE FORMS



700+ BEDS GLOBALLY



EXTENSIVE & DIVERSE VOLUNTEER DATABASE



PHASE-1 EXTENSIVE CAPABILITIES

- Single-Dose & Multiple-Dose Studies (Fed/Fasted)
- Comparative Pharmacokinetic (PK) Studies
- PK/PD Proof-of-Concept Studies
- Food Effect Studies
- Drug-Food and Drug-Drug Interaction Studies
- Drug-device Combination Studies
- Bridging Studies for Global Submissions
- First-in-Human and Early Phase Studies
- Controlled Substance Studies
- FDA-qualified for Schedule II-V
- Mixed Population Studies
- Biosimilar Clinical Pharmacology Studies
- Human Factor Studies
- Self-Administration Studies

EXECUTED 40+ PHASE-1 STUDIES

ADVANCED INFRASTRUCTURE AND OPERATIONAL SUPPORT

- First in the industry to implement IRIS-based subject registration system
- End-to-End Management of Investigational Products
- 24/7 medical coverage supported by advanced ICU facilities
- Real-time clinical data capture across all phases
- Integrated Safety and Bioanalytical Laboratory with automated Sample Management System
- Proven experience in mixed population studies
- Negative pressure inhalation chambers at Las Vegas Clinic for respiratory drug studies
- FDA-qualified to conduct studies involving Schedule II-V products

CENTRAL CLINICAL LAB

COMPREHENSIVE SERVICES FOR ALL PHASES OF CLINICAL TRIAL TESTING

ADVANCED BIOANALYTICAL EXPERTISE

METHOD DEVELOPMENT, VALIDATION AND SAMPLE ANALYSIS

1500+ VALIDATED METHODS

PEPTIDES EXPERIENCE

Proven Track Record in Early-Phase Peptide Studies Supporting FDA & EU Submissions

- Glucagon
- Octreotide
- Somatropin
- Leuprolide
- Semaglutide
- Leuprolide
- Semaglutide

PROVEN REGULATORY TRACK RECORD



NGCMA - India



Austria



Belgium



Brazil




Canada



Czech Republic



France



Germany



Gulf Cooperation Council



Hungary



Ireland



Italy



Kazakhstan



Latvia



Malaysia



Netherlands



Poland



Portugal



Slovakia



Spain



Thailand



Turkey



NABL



CAP

The logos of regulatory authorities are displayed solely for informational purposes and do not constitute endorsement or certification beyond the scope of authorized inspections and approvals.

Why Lambda?

- Digitalization of in-process activities (Central Lab, Clinical, Bioanalytical) for faster report generation.
- Bar-coded sample labeling for seamless digital scanning and tracking.
- Expertise in First-in-Human studies with global hybrid execution for global clients
- Proven leadership in biosimilars, oncology, dermatology, neuropsychiatry, and respiratory studies.
- State-of-the-art infrastructure with over 700 beds, 45+ LC MS/MS, and extensive global facilities in Ahmedabad & Mehsana (India), Las Vegas (USA), and Toronto (Canada).
- Trusted Experience: Conducted 7,500+ studies over 25 years, inspected by USFDA, EMA, MHRA, ANVISA, and NPRA Malaysia.

Connect with us to explore how we can accelerate your clinical trials.

BD@lambda-cro.com